RUN for the hills. SELL SELL SELL. When CapitalCube comes out with their article listing ETFs with "exposure" to your stock, it is the kiss of death. Personally I like REGN and think it is a good company, but I *HATE* when CapitalCube does this. Really? Exposure? How about "Investment"? How about "Insight"? Or "Hope" or "Faith"? I hate those idiots. It's like a self fulfilling prophecy with them. Idiots on Wall Street read that and sell on command like lemmings.
I REALLY THINK CAPITAL CUBE, THE MARKET REALIST, ZACKS ARE BUNCH SCAMMERS. ....WHY ELSE WOULD THEY RE-PRINT OULD NEWS, ENTER STORIES N YAHOO UNDER REGN WHEN REGN ISNT EVEN MENTIONED IN THE ARTICLE?
REGN looks very very attractive right now, it can easily reverse and surge back to 500 in no time.
This huge drop just doesn't make any sense. This past quarter we blew past estimates by $1/shr. Regn is opening up new indications for Dupi as well. 3rd quarter we're supposed to make even more $$$. Also the CP inhibitor. Not to mention new Eylea indications coming soon as well.
stock shoots up high as wall street likes eylea prospect
Hopefully institutional buyers will start to grasp that the dupixent competitors for dermatitis and asthma do not come with the same safety profile at least for now. Could take months.
The stock looks very attractive now, it gets oversold for no really good reason and can easily surge back to 470 - 480 area.
Does anyone understand why the asthma approval for dupixent isn't good news. I get how it is being hit with the news last week of competitors for skin application but this was supposed to be big news. Is the other news just so devestating?
Sanofi and Regeneron score asthma hit with dupilumab
BY Reuters — 2:31 AM ET 09/11/2017
PARIS, Sept 11 (Reuters) - Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market.
The companies said the drug - which is already approved under the brand name Dupixent for atopic dermatitis - met its two primary endpoints in a late-stage Phase III clinical study of patients with uncontrolled, persistent asthma.
GlaxoSmithKline's is currently leading the field in the treatment of asthma using injectable antibody drugs but rivals are closing in, with Sanofi and AstraZeneca ( AZN
) both seen as strong contenders.
At 52 weeks, dupilumab reduced severe asthma attacks by 46 percent in the overall population. In patients with high levels of so-called eosinophilic cells, reductions were between 60 and 67 percent. The drug also improved lung function.
Sanofi and Regeneron plan to submit an application to use the medicine in severe asthma to the U.S. Food and Drug Administration by the end of this year.
Elias Zerhouni, managing director and president of global research and development at Sanofi, said the results underscored the benefits of focusing on specific molecular pathways behind diseases.
"The positive data from this large second pivotal trial in uncontrolled persistent asthma, following the positive results of dupilumab in atopic dermatitis, further support this view in our opinion," he said. (Reporting by Sudip Kar-Gupta and Ben Hirschler; Editing by Biju Dwarakanath and John Stonestreet)
So the DUPI CAFE results that came out today, are those good? I'm no expert at reading them, but it seems like the SOLO2 study, 52/48 and 51/44 got EASI-75, but in the CAFE study, it went up to 59/63? That's opposite of what we got with the asthma results where Phase 3 was lower. Unless I'm totally misunderstanding lol...
A few analysts bashed the results due to P2 results being 60%, but the P3 results only showing 25% improvement.
UGH... what do you guys see as a catalyst to bring us back over $500? There is some Eylea P2 data due by EOY and earnings first week of Nov, but we got a major haircut on earnings this past quarter even though we beat by a freakin' DOLLAR. Can't believe this is almost back to the $360 low. A few more haircuts like -$56 these past 3 days and what was it, like -$60 after SNY reported earnings? Like seriously, how do people hate on earnings beat by a freakin DOLLAR?
this us seriously screwed up. very good b
Going back to 300s soon. Too much competition for Dupixant, sales ramp-up not as expected and there has been a slow uptake, company still relies on Eylea for most of it's profits after the debacle that has been Praluent. So considering all this, I don't think it deserves a premium valuation. Wall street seems to agree on that. 300 will be a good risk reward to go long REGN
To anyone with subject matter knowledge......was the news from 9/16 good for REGN?